Drug intelligence / Profile preview

Meklin

Development stage: Unknown
Lead developer: Bennet Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

**Meklin** is an oral fixed-dose antibacterial combination marketed by Bennet Pharmaceuticals. Each capsule contains **metronidazole 400 mg** and **tetracycline 333 mg**. Metronidazole is activated in susceptible anaerobic bacteria and protozoa to form reactive metabolites that damage microbial DNA, while tetracycline binds the bacterial 30S ribosomal subunit and inhibits protein synthesis. The product is used for susceptible mixed bacterial and protozoal infections, including gastrointestinal infections.

Brand names: Meklin
Other names: metronidazole + tetracyclinetetracycline + metronidazole

Targets

PXR (Pregnane X receptor)CXADR (Coxsackievirus and adenovirus receptor)M1 (Muscarinic acetylcholine receptor M1)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on Meklin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Meklin.

Explore the full profile